Source comparison
MK-677 Bone Density Research: Protocol Comparison
Elderly hip fracture patients (Murphy 2006) 25mg daily × 24 months +72% at 12 months Osteocalcin +90% at 12 months No significant femoral neck BMD change at 12 months; trend toward improvement at 24 months Biochemical activation confirmed but insufficient dura
This comparison does not assign a generated winner or score.
- Elderly hip fracture patients (Murphy 2006)
- 25mg daily × 24 months
- +72% at 12 months
- Osteocalcin +90% at 12 months
- No significant femoral neck BMD change at 12 months; trend toward improvement at 24 months
- Biochemical activation confirmed but insufficient duration to produce clinically meaningful density gains in compromised bone tissue
- Healthy elderly men/women (Chapman 1997)
- 25mg daily × 12 months
- +60% sustained
- Osteocalcin +55% by week 4
- Lumbar spine BMD +1.8% vs placebo
- Modest density gain in healthy elderly suggests preventive rather than therapeutic application
- Postmenopausal women (Svensson 1998)
- 25mg daily × 6 months
- +39% at 6 months
- Bone-specific ALP +40%
- No DEXA measurement performed
- Short duration limits conclusions. Marker response without density follow-up
- Growth hormone-deficient adults (Svensson 2004)
- 25mg daily × 52 weeks
- +88% peak at 8 weeks
- Osteocalcin +62% sustained
- Whole-body BMD +0.9% (not statistically significant)
- Largest IGF-1 response in deficient population but still minimal density gain. Suggests other limiting factors